← Back to Search

Progestin

Depo-Provera Injectable Product for Delayed Onset of Lactation

Phase 4
Waitlist Available
Led By Maria Gallo, PhD
Research Sponsored by Ohio State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Intend to reside in Ohio or Georgia for the first 12 months after delivery.
Intend to deliver in the Labor and Delivery Unit at Ohio State University Wexner Medical Center, Grady Memorial Hospital or Emory University Midtown;
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 12 months postpartum
Awards & highlights

Study Summary

This trial will test whether giving DMPA to women immediately postpartum, while they are still in the hospital, will increase breastfeeding and long-term contraceptive use compared to no injection or placebo.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 12 months postpartum
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 12 months postpartum for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to lactogenesis stage 2
Use of highly-effective contraception

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Intervention armExperimental Treatment1 Intervention
Intramuscular injectable depot medroxyprogesterone acetate (1 mL of medroxyprogesterone acetate sterile aqueous suspension 150 mg/mL) provided within 48 hours of childbirth
Group II: Open armActive Control1 Intervention
No intervention provided
Group III: Placebo armPlacebo Group1 Intervention
0.9% sodium chloride injection provided within 48 hours of childbirth

Find a Location

Who is running the clinical trial?

Ohio State UniversityLead Sponsor
821 Previous Clinical Trials
501,086 Total Patients Enrolled
Nationwide Children's HospitalOTHER
337 Previous Clinical Trials
5,220,105 Total Patients Enrolled
Emory UniversityOTHER
1,627 Previous Clinical Trials
2,560,716 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this trial pioneering a new field of research?

"As of now, 10 ongoing research initiatives concerning Depo-Provera Injectable Product are taking place in 37 cities and 7 nations. The initial clinical trial for this drug was organized by Novartis Pharmaceuticals back in 2015 and it had a participant pool of 74 patients that successfully concluded Phase 2 testing. Since then, 315 such studies have been conducted."

Answered by AI

How reliable is Depo-Provera Injectable Product in terms of safety?

"The safety rating for this particular product is a 3 due to the fact that it has reached Phase 4, indicating approval from governing bodies."

Answered by AI

Is the recruitment process for this experiment still active?

"Affirmative. According to information hosted on clinicaltrials.gov, this medical trial is currently in search of participants. This study was initially posted on March 21st 2019 and has been updated as recently as May 11th 2021. 800 patients are needed at a single site for the duration of the experiment."

Answered by AI

What have physicians prescribed Depo-Provera Injectable Product to treat?

"Depo-Provera Injectable Product is frequently employed to address vasomotor symptoms of menopause, but can also be useful for endometrial hyperplasia management and relief from other pain. It has additionally been used as a form of contraception."

Answered by AI

What is the aggregate amount of people participating in this experiment?

"Affirmative. The data found on clinicaltrials.gov attests that this medical experiment, posted March 21st 2019 and revised May 11th 2021, is actively looking for participants. 800 patients need to be enrolled across a single site."

Answered by AI
~8 spots leftby Mar 2025